Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chantix, Zyban Safety Issues Put Focus On REMS Assessment Efforts

Executive Summary

GlaxoSmithKline is writing a questionnaire to ascertain whether patients receiving the firm's smoking cessation drug Zyban understand the risk of potential neuropsychiatric side effects

You may also be interested in...



Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M

The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.

Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M

The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.

FDA Diabetes Guidance Encourages Enrollment Of Sicker Patients

In raising pre-market safety standards, FDA says that development time will not necessarily increase if a robust protocol is used.

Related Content

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel